{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-23-000045","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.174622+00:00","generated_at":"2026-06-12T08:59:34.966268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"10x Genomics Q2 revenue $146.8M (+28% YoY); raises FY2023 guidance to $600-620M","bullets":["Revenue $146.8M in Q2, +28% YoY from $114.6M.","Gross margin 68% vs 76% prior year, down on product mix from new launches.","Net loss $62.4M vs $64.5M YoY; stock-based compensation expense $45.7M.","Raises FY2023 revenue guidance to $600-620M from prior $590-610M, 16-20% growth.","Accelerated Xenium in situ platform momentum; launched Visium CytAssist Gene & Protein Expression assay."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-23-000045","json":"https://secwatch.observer/filing/0001770787-23-000045.json","markdown":"https://secwatch.observer/filing/0001770787-23-000045.md","text":"https://secwatch.observer/filing/0001770787-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/txg-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:59:34.966268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3352f706dc4d17e027da507a0398d98f9c9b2f9","claim":"10x Genomics, Inc. reported the second quarter ended June 30, 2023 results: revenue $146.8 million, net income Net loss was $62.4 million. Guidance raised.","evidence_excerpt":"Revenue was $146.8 million for the second quarter of 2023, a 28% increase from $114.6 million for the corresponding prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$146.8 million"},{"label":"Net income","value":"Net loss was $62.4 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f93db7b6388b40f3cfe078ec9cf679d0f8744f5e","claim":"10x Genomics, Inc. reported full year 2023 results: revenue $600 million to $620 million. Guidance raised.","evidence_excerpt":"10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $600 million to $620 million, representing 16% to 20% growth over full year 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000045/0001770787-23-000045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$600 million to $620 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}